相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Updating progress in sarcoma therapy with mTOR inhibitors
J. -Y. Blay
ANNALS OF ONCOLOGY (2011)
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2011)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKBI-deficient mice
J. M. Garcia-Martinez et al.
BRITISH JOURNAL OF CANCER (2011)
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
Beverly L. Falcon et al.
CANCER RESEARCH (2011)
Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Irene M. Ghobrial et al.
LANCET ONCOLOGY (2011)
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Stephen M. Ansell et al.
LANCET ONCOLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
B. Weigelt et al.
ONCOGENE (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
Bao Hoang et al.
BLOOD (2010)
Phase 1 and Pharmacokinetic Study of Everolimus, a Mammalian Target of Rapamycin Inhibitor, in Combination With Docetaxel for Recurrent/Refractory Nonsmall Cell Lung Cancer
Suresh S. Ramalingam et al.
CANCER (2010)
A Phase 2 Study of the Oral Mammalian Target of Rapamycin Inhibitor, Everolimus, in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
CANCER (2010)
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Andrew C. Hsieh et al.
CANCER CELL (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2010)
Target of Rapamycin Signaling in Leukemia and Lymphoma
Collin Vu et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini et al.
CLINICAL CANCER RESEARCH (2010)
The mTOR Pathway: A New Target in Cancer Therapy
L. Ciuffreda et al.
CURRENT CANCER DRUG TARGETS (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sebastien Albert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
Sarah M. Temkin et al.
GYNECOLOGIC ONCOLOGY (2010)
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Jonathan D. Powell et al.
IMMUNITY (2010)
Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A comprehensive map of the mTOR signaling network
Etienne Caron et al.
MOLECULAR SYSTEMS BIOLOGY (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
Nathalie Carayol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
Ryan J. O. Dowling et al.
BIODRUGS (2009)
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
David T. Teachey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
Robert J. Amato et al.
CANCER (2009)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Alexander E. Perl et al.
CLINICAL CANCER RESEARCH (2009)
Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature
M. E. A. P. M. Adriaensen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S. Farag et al.
LEUKEMIA RESEARCH (2009)
Common corruption of the mTOR signaling network in human tumors
S Menon et al.
ONCOGENE (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
Jessica K. Altman et al.
CURRENT OPINION IN HEMATOLOGY (2008)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Mechanism of action of rapalogues: the antiangiogenic hypothesis
Sandrine Faivre et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCICIND-148
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the eastern cooperative oncology group (E1500)
Kishan J. Pandya et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives
Joseph Gligorov et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
分享论文
